These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 25691059

  • 21. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
    Pin RH, Reinblatt M, Fong Y.
    Ann Surg; 2004 Oct; 240(4):659-65; discussion 665-6. PubMed ID: 15383793
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic efficacy of improved α-fetoprotein promoter-mediated tBid delivered by folate-PEI600-cyclodextrin nanopolymer vector in hepatocellular carcinoma.
    Hu BG, Liu LP, Chen GG, Ye CG, Leung KK, Ho RL, Lin MC, Lai PB.
    Exp Cell Res; 2014 Jun 10; 324(2):183-91. PubMed ID: 24726886
    [Abstract] [Full Text] [Related]

  • 23. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
    Cao Y, Chen J, Wang D, Peng H, Tan X, Xiong D, Huang A, Tang H.
    Oncotarget; 2015 Nov 10; 6(35):38093-106. PubMed ID: 26497554
    [Abstract] [Full Text] [Related]

  • 24. [Killing effect of PNP/MeP-dR suicide gene system driven by an AFP promoter AF0.3 on AFP-positive hepatoma cells].
    Cai XK, Zhou JL, Zhou HJ, Zhang L, Wu JH, Lin JS.
    Ai Zheng; 2006 Nov 10; 25(11):1334-9. PubMed ID: 17094897
    [Abstract] [Full Text] [Related]

  • 25. Insulation from viral transcriptional regulatory elements enables improvement to hepatoma-specific gene expression from adenovirus vectors.
    Ye X, Liang M, Meng X, Ren X, Chen H, Li ZY, Ni S, Lieber A, Hu F.
    Biochem Biophys Res Commun; 2003 Aug 08; 307(4):759-64. PubMed ID: 12878174
    [Abstract] [Full Text] [Related]

  • 26. [Gene therapy using a dominant negative form of the protein phosphatase 2A catalytic subunit a driven by a hepatoma tissue-specific promoter achieves effective growth inhibition of hepatoma cells].
    Li DM, Li W, Tao M, Chen K, Gong FR, Xu ZK, Chen Z.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jun 08; 21(6):459-63. PubMed ID: 24034849
    [Abstract] [Full Text] [Related]

  • 27. [Construction and study of replication-defective adenovirus targeting hepatocarcinoma].
    Xu DY, Du ZY, Wang Y, Chen HH, Xu YJ, Lu YL.
    Ai Zheng; 2006 Jul 08; 25(7):798-804. PubMed ID: 16831267
    [Abstract] [Full Text] [Related]

  • 28. Adenovirus-mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth.
    Wang M, Liu J, Xi D, Luo X, Ning Q.
    J Gene Med; 2016 Jul 08; 18(7):102-11. PubMed ID: 27163335
    [Abstract] [Full Text] [Related]

  • 29. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent.
    Park MY, Park YS, Nam JH.
    Int J Oncol; 2011 Oct 08; 39(4):853-61. PubMed ID: 21701774
    [Abstract] [Full Text] [Related]

  • 30. Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma.
    Miao J, Chen GG, Chun SY, Yun JP, Chak EC, Ho RL, Lai PB.
    Int J Cancer; 2006 Oct 15; 119(8):1985-93. PubMed ID: 16708390
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y, Liu T, Huang P, Zhao H, Zhang R, Ma B, Chen K, Huang F, Zhou X, Cui C, Liu X.
    Oncotarget; 2015 May 30; 6(15):13564-78. PubMed ID: 25980438
    [Abstract] [Full Text] [Related]

  • 34. Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma.
    Lu SY, Sui YF, Li ZS, Pan CE, Ye J, Wang WY.
    World J Gastroenterol; 2003 Apr 30; 9(4):688-91. PubMed ID: 12679911
    [Abstract] [Full Text] [Related]

  • 35. Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein.
    Jin YN, Chung HK, Kang JH, Lee YJ, Kimm KI, Kim YJ, Kim S, Chung JK.
    Cancer Biother Radiopharm; 2008 Oct 30; 23(5):551-60. PubMed ID: 18986218
    [Abstract] [Full Text] [Related]

  • 36. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.
    Ohashi M, Kanai F, Tateishi K, Taniguchi H, Marignani PA, Yoshida Y, Shiratori Y, Hamada H, Omata M.
    Biochem Biophys Res Commun; 2001 Mar 30; 282(2):529-35. PubMed ID: 11401492
    [Abstract] [Full Text] [Related]

  • 37. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene.
    Kunitomi M, Takayama E, Suzuki S, Yasuda T, Tsutsui K, Nagaike K, Hiroi S, Tadakuma T.
    Jpn J Cancer Res; 2000 Mar 30; 91(3):343-50. PubMed ID: 10760695
    [Abstract] [Full Text] [Related]

  • 38. The targeted expression of interleukin-2 in human hepatocellular carcinoma cells.
    He P, Tang ZY, Ye SL, Liu BB, Liu YK.
    J Exp Clin Cancer Res; 2000 Jun 30; 19(2):183-7. PubMed ID: 10965816
    [Abstract] [Full Text] [Related]

  • 39. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions.
    Yoon AR, Hong J, Kim M, Yun CO.
    Sci Rep; 2018 Feb 02; 8(1):2233. PubMed ID: 29396500
    [Abstract] [Full Text] [Related]

  • 40. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X, Cao X, Wei R, Cai Y, Li H, Gui J, Zhong D, Liu XY, Huang K.
    Cancer Gene Ther; 2012 Jan 02; 19(1):49-57. PubMed ID: 21979578
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.